Chair: M. Aapro, CH (ESO) - P. Casali, IT (ESMO)
The European School of Oncology (ESO) bought together a group of experts in 2013 from different fields in oncology which became the Innovation Task Force (summarized in the January 2014 issue of CancerWorld) to address the following questions:
- How do we define innovation in cancer care?
- On what basis should we select priority innovations that should be made available to patients? How does one measure the value of innovation?
- What barriers exist in the uptake of innovations across Europe?
- What concrete measures can be taken to overcome these barriers, and foster an innovative culture across cancer care?
At the European Cancer Care Organisation (ECCO) meeting in Amsterdam in 2015 a Special session was dedicated to this topic and the present set of slides comprises the presentations made by experts convened by ESO in Luxemburg on October 19, 2016 in a special workshop on "Access to treatment, definition of innovation and obsolescence in cancer treatments" before a meeting of the European Comisssion Cancer Experts meeting. ESO supports ECCO in developing a position paper presenting a multidisciplinary perspective on how ECCO and its member organisations can responsibly and sustainably encourage access to the most meaningful innovations for cancer patients in years to come, while also addressing obsolete practices.
M. Aapro, Clinique de Genolier, Oncology Dpt., Genolier, CH
P. Casali, National Cancer Institute, Medical Oncology Dept., Milano, IT
A. Ciabattoni, San Filippo Neri Hospital, Department of Radiotherapy, Rome, IT
M. Dicato, Centre Hospitalier de Luxembourg, Dept. of Hematology-Oncology, Luxembourg, LU
D. Lacombe, EORTC Data Center, NDDP, Brussels, BE
N. Mottet, University Jean Monnet, Dept. of Urology, Saint Etienne, FR
F. Pignatti, European Medicines Agency, Scientific & Regulatory Management Department Oncology, Haematology & Diagnostics, London, UK
I. van den Neucker, ECCO - the European CanCer Organisation, Brussels, BE
The ESO initiative on Innovation and Obsolescence
M. Aapro, CH
Is robotic surgery a must in prostate cancer?
N. Mottet, FR
Perioperative radiation therapy: why not yet a cost-saving standard in breast cancer?
A. Ciabattoni, IT
An example of innovation: immuno-oncology
M. Dicato, LU
ESMO initiatives on access to treatment
P. Casali, IT
The EMA position on accepting innovative agents
F. Pignatti, UK
EORTC: Innovative Drugs in a new environment
D. Lacombe, BE
A draft position of ECCO
I. van den Neucker, BE
Moderated discussion with the audience led by
M. Aapro and P. Casali, IT